Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

566
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
566
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

494
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
494
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

695
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
695
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

554
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
554

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trends in cardiac implantable electronic device infections: 2015 to 2019.

BMC cardiovascular disorders·2026
Same author

Antimicrobial Efficacy of a Taurolidine-Based Antimicrobial Compound on Contaminated Surfaces Simulated in a Standardized 4-Field Test.

Advanced healthcare materials·2025
Same author

Conduction system pacing for pacing-induced cardiomyopathy: Could the cure be worse than the ill?

Heart rhythm·2025
Same author

Left bundle branch block-Innocent bystander, silent menace, or both.

Heart rhythm·2025
Same author

Prevalence of cardiac implantable electronic device infections in Germany in 2015.

Scientific reports·2024
Same author

Misuse of Guidelines Could Disadvantage and Harm Patients.

Journal of evidence-based medicine·2024

Related Experiment Video

Updated: Mar 10, 2026

Bidirectional Electrical and Optoelectronic Interfaces in Healthy and Ischemic Ex Vivo Rat Hearts
08:33

Bidirectional Electrical and Optoelectronic Interfaces in Healthy and Ischemic Ex Vivo Rat Hearts

Published on: July 18, 2025

991

Technologies for Prolonging Cardiac Implantable Electronic Device Longevity.

Ernest W Lau1

  • 1Department of Cardiology, Royal Victoria Hospital, Belfast, UK.

Pacing and Clinical Electrophysiology : PACE
|December 13, 2016
PubMed
Summary

Extending the longevity of cardiac implantable electronic devices (CIEDs) is crucial for patient health and healthcare systems. Optimizing battery capacity, chemistry, and architecture can significantly prolong device life, reducing replacement needs.

Keywords:
CIEDbatterydevice replacementdevice revisionlongevity

More Related Videos

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

26.9K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K

Related Experiment Videos

Last Updated: Mar 10, 2026

Bidirectional Electrical and Optoelectronic Interfaces in Healthy and Ischemic Ex Vivo Rat Hearts
08:33

Bidirectional Electrical and Optoelectronic Interfaces in Healthy and Ischemic Ex Vivo Rat Hearts

Published on: July 18, 2025

991
A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

26.9K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K

Area of Science:

  • Biomedical Engineering
  • Materials Science
  • Cardiology

Background:

  • Cardiac implantable electronic devices (CIEDs) are essential for managing cardiac conditions but are limited by non-rechargeable battery life.
  • Device replacement due to battery exhaustion poses risks, costs, and logistical challenges for patients and healthcare systems.
  • Prolonging CIED longevity is necessary to align with increasing patient life expectancy and improve quality of life.

Purpose of the Study:

  • To analyze the factors influencing the longevity of CIED batteries.
  • To explore strategies for extending CIED operational lifespan.
  • To empower healthcare professionals and purchasers with knowledge for informed device selection.

Main Methods:

  • Review of CIED battery technology, including capacity, chemistry, and internal architecture.
  • Analysis of CIED energy consumption patterns (e.g., pacing, telemetry, shocks).
  • Evaluation of the relationship between battery design and device longevity.

Main Results:

  • CIED longevity is primarily determined by battery energy reserve attrition.
  • Battery capacity, chemistry, and architecture are key determinants of energy storage and device lifespan.
  • Patient clinical needs significantly influence energy usage, while manufacturers control stored energy.

Conclusions:

  • Improving battery capacity, chemistry, and architecture can enhance CIED longevity.
  • Informed selection of CIED models and utilization of energy-saving features can prolong device life.
  • Extended CIED longevity benefits patients through reduced risks and costs and benefits healthcare systems through resource optimization.